PURPOSE: α-Pyrrolidinovalerophenone (α-PVP) is a second-generation synthetic cathinone which acts as an inhibitor at the dopamine and norepinephrine transporters in the brain. These novel studies determined the pharmacokinetics (PK) of α-PVP in rats and then evaluated the effects of an α-PVP vaccine on the PK profile. METHODS: Adult male Sprague-Dawley rats were randomly divided into treatment groups (n = 24/group) in which the vaccinated rats received an initial and two booster immunizations of the α-PVP vaccine at 0, 3, and 9 wks. Control rats received saline injections. α-PVP (0.56, 1, 3 mg/kg, sc) was then administered to both groups between 11-12 weeks and serum samples were collected for determination of α-PVP serum concentrations by LC-MS/MS (n=6 rats/treatment/time). At 13 weeks, brain, heart and kidney concentrations of α-PVP were determined by LC-MS/MS after administration of 1 mg/kg α-PVP (n=4-5 rats/treatment/time). RESULTS: PK values in control rats showed dose-dependent increases in maximum serum concentrations (Cmax) and area under the curve (AUCinf) values with an elimination half-life (t1/2) of approximately 2.1 h. α-PVP exhibited linear PK profile in control rats. Vaccinated rats had significantly (p<0.05) higher serum Cmax and AUCinf values than controls, and significantly reduced total body clearance, volume of distribution and t1/2 values. Vaccinated rats had significantly lower α-PVP concentrations in the brain, heart, and kidney in comparison to control rats at early time points. CONCLUSION: Vaccination with the novel α-PVP vaccine significantly altered serum PK leading to a time-dependent reduction in brain, kidney and heart concentrations of α-PVP compared to controls.
PURPOSE: α-Pyrrolidinovalerophenone (α-PVP) is a second-generation synthetic cathinone which acts as an inhibitor at the dopamine and norepinephrine transporters in the brain. These novel studies determined the pharmacokinetics (PK) of α-PVP in rats and then evaluated the effects of an α-PVP vaccine on the PK profile. METHODS: Adult male Sprague-Dawley rats were randomly divided into treatment groups (n = 24/group) in which the vaccinated rats received an initial and two booster immunizations of the α-PVP vaccine at 0, 3, and 9 wks. Control rats received saline injections. α-PVP (0.56, 1, 3 mg/kg, sc) was then administered to both groups between 11-12 weeks and serum samples were collected for determination of α-PVP serum concentrations by LC-MS/MS (n=6 rats/treatment/time). At 13 weeks, brain, heart and kidney concentrations of α-PVP were determined by LC-MS/MS after administration of 1 mg/kg α-PVP (n=4-5 rats/treatment/time). RESULTS: PK values in control rats showed dose-dependent increases in maximum serum concentrations (Cmax) and area under the curve (AUCinf) values with an elimination half-life (t1/2) of approximately 2.1 h. α-PVP exhibited linear PK profile in control rats. Vaccinated rats had significantly (p<0.05) higher serum Cmax and AUCinf values than controls, and significantly reduced total body clearance, volume of distribution and t1/2 values. Vaccinated rats had significantly lower α-PVP concentrations in the brain, heart, and kidney in comparison to control rats at early time points. CONCLUSION: Vaccination with the novel α-PVP vaccine significantly altered serum PK leading to a time-dependent reduction in brain, kidney and heart concentrations of α-PVP compared to controls.
Authors: Michael J McCluskie; Jennifer Thorn; Paul R Mehelic; Parag Kolhe; Keshab Bhattacharya; Jari I Finneman; David R Stead; Michele Bailey Piatchek; Ningli Zhang; Ghania Chikh; Janna Cartier; Dana M Evans; James R Merson; Heather L Davis Journal: Int Immunopharmacol Date: 2015-02-28 Impact factor: 4.932
Authors: B S Fox; K M Kantak; M A Edwards; K M Black; B K Bollinger; A J Botka; T L French; T L Thompson; V C Schad; J L Greenstein; M L Gefter; M A Exley; P A Swain; T J Briner Journal: Nat Med Date: 1996-10 Impact factor: 53.440
Authors: Jacques D Nguyen; Paul T Bremer; Alex Ducime; Kevin M Creehan; Brent R Kisby; Michael A Taffe; Kim D Janda Journal: Neuropharmacology Date: 2016-12-09 Impact factor: 5.250
Authors: Paul T Bremer; Joel E Schlosburg; Matthew L Banks; Floyd F Steele; Bin Zhou; Justin L Poklis; Kim D Janda Journal: J Am Chem Soc Date: 2017-06-20 Impact factor: 15.419
Authors: Misty W Stevens; Rachel L Tawney; C Michael West; Alicia D Kight; Ralph L Henry; S Michael Owens; W Brooks Gentry Journal: MAbs Date: 2013-12-23 Impact factor: 5.857